title: Vascular marker expression during the development of various types of gynaecological malignancy.
abstract: Clinical diagnosis of gynaecological malignancies is usually successful in the advanced stages of the tumour, and this has a major impact on the success of therapy. Therefore, in the last few years, cancer research has tried to identify and characterise new biochemical and molecular markers needed as predictive indicators for the diagnosis of cancer. Our aim has been to search the molecular changes in gene expression of death receptor 6, glycoprotein M6B (Gpm6B) and genes associated with tumours of the female genital system. After isolation of messenger RNA (mRNA), transcription of mRNA into the cDNA was performed. The quantification of gene expression changes was detected using the reverse transcription polymerase chain reaction (RT-PCR) method. Analysis at the protein level was performed using the Western blot method. In both methods, we used actin as a housekeeping gene for normalisation. Numerical quantification of changes in expression and in the level of the specific proteins was evaluated using the Data Syngene program. Significant changes in the levels of protein and mRNA expression were detected, mainly in the death receptor 6 (Dr6) gene of patients suffering from cancer of the corpus and cervix uteri and ovarian cancer, which also corresponded with the level of protein Dr6. At the level of transcription, a significant increase in the expression levels of mRNA for the Gpm6B gene was detected, which led to an increase in corresponding protein in the peripheral blood of patients with gynaecological tumours against the healthy control group. This article could help to find an adequate marker for clinical application that will enable more sensitive detection of the early stages of gynaecological malignancies from the peripheral blood of patients.
authors.affiliation: Department of Medical and Clinical Biochemistry, Faculty of Medicine, Pavol Jozef Safarik University, Kosice, Slovak Republic.
authors.forename: Peter
authors.initials: P
authors.lastname: Urban
authors.forename: Miroslava Bilecova
authors.initials: MB
authors.lastname: Rabajdova
authors.forename: Jan
authors.initials: J
authors.lastname: Varga
authors.forename: Peter
authors.initials: P
authors.lastname: Kruzliak
authors.forename: Viera
authors.initials: V
authors.lastname: Fialkovicova
authors.forename: Eva
authors.initials: E
authors.lastname: Durovcova
authors.forename: Maria
authors.initials: M
authors.lastname: Marekova
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D015153:Blotting, Western; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D005833:Genital Neoplasms, Female / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008562:Membrane Glycoproteins / Q000235:genetics / Q000378:metabolism*; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism*; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D018124:Receptors, Tumor Necrosis Factor / Q000235:genetics / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D014408:Biomarkers, Tumor; C484160:GPM6B protein, human; D008562:Membrane Glycoproteins; D009419:Nerve Tissue Proteins; D012333:RNA, Messenger; D018124:Receptors, Tumor Necrosis Factor; C114109:TNFRSF21 protein, human
references.citation: Science. 2000 Aug 18;289(5482):1197-202
references.pmid: 10947988
references.citation: Eur J Cancer. 2010 Mar;46(4):765-81
references.pmid: 20116997
references.citation: BMC Cancer. 2010 Aug 16;10:429
references.pmid: 20712874
references.citation: Cancer J. 2012 Jul-Aug;18(4):338-42
references.pmid: 22846735
references.citation: FASEB J. 2009 Jun;23(6):1625-37
references.pmid: 19141537
references.citation: Blood. 2005 Jan 15;105(2):679-81
references.pmid: 15358628
references.citation: Am J Obstet Gynecol. 2012 Jul;207(1):36.e1-8
references.pmid: 22727345
references.citation: Clin Chem. 2006 Sep;52(9):1701-12
references.pmid: 16873292
references.citation: J Clin Oncol. 2007 Mar 1;25(7):852-61
references.pmid: 17327606
references.citation: J Mol Neurosci. 2009 Mar;37(3):191-200
references.pmid: 18581270
references.citation: Adv Exp Med Biol. 2009;647:186-94
references.pmid: 19760075
references.citation: FEBS Lett. 2005 May 9;579(12):2569-75
references.pmid: 15862292
references.citation: Clin Cancer Res. 2012 Oct 15;18(20):5806-15
references.pmid: 22912389
references.citation: Postepy Hig Med Dosw (Online). 2007;61:122-8
references.pmid: 17369780
references.citation: Cancer Cell. 2007 Jun;11(6):539-54
references.pmid: 17560335
references.citation: PLoS One. 2012;7(5):e36525
references.pmid: 22567163
references.citation: Cancer Immunol Immunother. 2008 Jun;57(6):777-87
references.pmid: 17962943
references.citation: Cancer Biol Ther. 2011 Aug 1;12(3):169-80
references.pmid: 21617380
references.citation: Am J Obstet Gynecol. 2007 Mar;196(3):243.e1-5
references.pmid: 17346538
references.citation: N Engl J Med. 2008 Jan 31;358(5):502-11
references.pmid: 18234754
references.citation: Expert Rev Anticancer Ther. 2009 Aug;9(8):1115-23
references.pmid: 19671031
references.citation: Neurogenetics. 2006 Mar;7(1):31-7
references.pmid: 16416265